← All trials
NCT04683926
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2020
- Primary completion
- Jan 18, 2021
- Completion date
- Jan 18, 2021
- First posted
- Dec 24, 2020
- Last posted
- Dec 24, 2020
- Enrollment
- 24
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Syntrix Biosystems, Inc.Lead sponsor
- National Institute on Drug Abuse (NIDA)Collaborator
- Syntrix Biosystems, Inc.Study director
- CelerionCollaborator
- CelerionOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.